Novel Imidazopyrazines as Cyclin Dependent Kinase Inhibitors

P 2006

Novel Imidazopyrazines as Cyclin Dependent Kinase Inhibitors

GUZI, Timothy, Kamil PARUCH, Michael DWYER, Lianyun ZHAO, Patrick CURRAN et. al.

Základní údaje

Originální název

Novel Imidazopyrazines as Cyclin Dependent Kinase Inhibitors

Název česky

Novel Imidazopyrazines as Cyclin Dependent Kinase Inhibitors

Autoři

GUZI, Timothy, Kamil PARUCH, Michael DWYER, Lianyun ZHAO, Patrick CURRAN, David BELANGER, Blake HAMANN, Panduranga REDDY a Arshad SIDDIQUI

Vydání

Číslo: US 2006106023 A1, Vydavatel: United States Patent and Trademark Office, Místo vydání: USA, Název vlastníka: Schering-Plough, 2006

Další údaje

Jazyk

angličtina

Typ výsledku

Patent

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Organizační jednotka

Přírodovědecká fakulta

Klíčová slova česky

imidazopyrazine; cyclin dependent kinase; inhibitor

Klíčová slova anglicky

imidazopyrazine; cyclin dependent kinase; inhibitor

Štítky

Cyclin dependent kinase, imidazopyrazine, inhibitor

Změněno: 25. 6. 2009 15:05, doc. Mgr. Kamil Paruch, Ph.D.

Anotace

ORIG CZ

V originále

In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compds. of formula I [R = H, halo, (un)substituted-aryl, -heteroaryl, -cycloalkyl, etc.; R1 = H, halo or alkyl; R2 = halo, (un)substituted-alkyl, -aryl, -arylalkyl, etc.; R3 = H, (un)substituted-aryl, -heteroaryl, -heterocyclyl, etc.] as inhibitors of cyclin dependent kinases, methods of prepg. such compds., pharmaceutical compns. contg. one or more such compds., methods of prepg. pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepd. by condensation of 8-chloro-3-methylimidazo[1,2-a]pyrazine with 4-(aminomethyl)pyridine. I possessed excellent CDK inhibitory properties, e.g., II demonstrated an IC50 value of 22.5 .mu.M.

Česky

viz Anotace

Citovat

GUZI, Timothy, Kamil PARUCH, Michael DWYER, Lianyun ZHAO, Patrick CURRAN, David BELANGER, Blake HAMANN, Panduranga REDDY a Arshad SIDDIQUI. Novel Imidazopyrazines as Cyclin Dependent Kinase Inhibitors. 2006. Patent. Číslo: US 2006106023 A1. Vydavatel: United States Patent and Trademark Office. Místo vydání: USA. Název vlastníka: Schering-Plough. Datum registrace: 10. 11. 2005. Datum přijetí: 18. 5. 2006.

@misc{838349,
   author = {Guzi, Timothy and Paruch, Kamil and Dwyer, Michael and Zhao, Lianyun and Curran, Patrick and Belanger, David and Hamann, Blake and Reddy, Panduranga and Siddiqui, Arshad},
   keywords = {imidazopyrazine; cyclin dependent kinase; inhibitor},
   language = {eng},
   title = {Novel Imidazopyrazines as Cyclin Dependent Kinase Inhibitors},
   year = {2006}
}

TY  - PAT
ID  - 838349
AU  - Guzi, Timothy - Paruch, Kamil - Dwyer, Michael - Zhao, Lianyun - Curran, Patrick - Belanger, David - Hamann, Blake - Reddy, Panduranga - Siddiqui, Arshad
PY  - 2006
TI  - Novel Imidazopyrazines as Cyclin Dependent Kinase Inhibitors
KW  - imidazopyrazine
KW  - cyclin dependent kinase
KW  - inhibitor
N2  - In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyrazine compds. of formula I [R = H, halo, (un)substituted-aryl, -heteroaryl, -cycloalkyl, etc.; R1 = H, halo or alkyl; R2 = halo, (un)substituted-alkyl, -aryl, -arylalkyl, etc.; R3 = H, (un)substituted-aryl, -heteroaryl, -heterocyclyl, etc.] as inhibitors of cyclin dependent kinases, methods of prepg. such compds., pharmaceutical compns. contg. one or more such compds., methods of prepg. pharmaceutical formulations comprising one or more such compds., and methods of treatment, prevention, inhibition, or amelioration of one or more diseases assocd. with the CDKs using such compds. or pharmaceutical compns. Thus, e.g., II was prepd. by condensation of 8-chloro-3-methylimidazo[1,2-a]pyrazine with 4-(aminomethyl)pyridine. I possessed excellent CDK inhibitory properties, e.g., II demonstrated an IC50 value of 22.5 .mu.M.
ER  -

GUZI, Timothy, Kamil PARUCH, Michael DWYER, Lianyun ZHAO, Patrick CURRAN, David BELANGER, Blake HAMANN, Panduranga REDDY a Arshad SIDDIQUI. \textit{Novel Imidazopyrazines as Cyclin Dependent Kinase Inhibitors}. 2006. Patent. Číslo: US 2006106023 A1. Vydavatel: United States Patent and Trademark Office. Místo vydání: USA. Název vlastníka: Schering-Plough. Datum registrace: 10. 11. 2005. Datum přijetí: 18. 5. 2006.

Podrobný výpis o publikaci